financetom
Business
financetom
/
Business
/
Allstate Likely to See Earnings Rebound in 2024, BofA Securities Says
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Allstate Likely to See Earnings Rebound in 2024, BofA Securities Says
Mar 28, 2024 9:23 AM

12:12 PM EDT, 03/28/2024 (MT Newswires) -- Allstate ( ALL ) is poised for a "reversal of fortune," with an earnings rebound in 2024 to continue through 2026 as its 2023 rate increases are expected to push the company's underwriting margins, BofA Securities said in a Thursday note.

The company could even surpass its multi-year margin records given its rate increases and BofA Securities said this was the "key motivation" that led it to raise earmings-per-share estimates for 2025 and 2026.

"Allstate ( ALL ) is likely to be over-earning long-term margin expectations by the equivalent of around $1.30," said the investment firm.

BofA Securities reiterated its buy rating on Allstate ( ALL ), with an increased price target of $209 from $189.

BofA Securities also raised its price targets for insurers Progressive (PGR) and Travelers (TRV).

Price: 173.02, Change: +3.18, Percent Change: +1.87

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
State officials call on top funds to vote against two Exxon directors
State officials call on top funds to vote against two Exxon directors
May 21, 2024
BOSTON (Reuters) - A group of state financial officers and other public and labor leaders on Tuesday called for major asset managers to vote against top Exxon directors, citing the company's lawsuit against climate activists. The group including California Treasurer Fiona Ma and New York City Comptroller Brad Lander called for votes against Exxon CEO Darren Woods and the company's...
JD.com Prices Upsized $1.75 Billion Convertible Senior Notes Offering, Plans to Repurchase 14 Million ADSs
JD.com Prices Upsized $1.75 Billion Convertible Senior Notes Offering, Plans to Repurchase 14 Million ADSs
May 21, 2024
10:13 AM EDT, 05/21/2024 (MT Newswires) -- JD.com ( JD ) said Tuesday it has priced an offering of $1.75 billion of its convertible senior notes to qualified institutional buyers. The offering, which was upsized from the initial $1.5 billion, is set to close around Thursday. The initial conversion rate of the notes is 21.8830 American depositary shares per $1,000...
Update: XPeng Shares Rise After Q1 Non-GAAP Loss Narrows, Revenue Increases
Update: XPeng Shares Rise After Q1 Non-GAAP Loss Narrows, Revenue Increases
May 21, 2024
10:14 AM EDT, 05/21/2024 (MT Newswires) -- (Updates with the latest stock price movement in the headline and first paragraph.) XPeng ( XPEV ) shares were up nearly 13% in recent Tuesday trading after the company's Q1 non-GAAP loss narrowed year-over-year while revenue rose. The company reported a Q1 non-GAAP net loss of 1.49 Chinese renminbi ($0.21) per diluted American...
GSK Says Depemokimab Reduced Asthma Attacks in 2 Late-Stage Studies
GSK Says Depemokimab Reduced Asthma Attacks in 2 Late-Stage Studies
May 21, 2024
10:15 AM EDT, 05/21/2024 (MT Newswires) -- GSK (GSK) said Tuesday that its depemokimab reduced asthma attacks in two phase 3 clinical trials that evaluated the efficacy and safety of the potential treatment compared with placebo in patients with severe asthma. The trials met their primary endpoints of a lower annualized rate of clinically significant asthma attacks over 52 weeks,...
Copyright 2023-2026 - www.financetom.com All Rights Reserved